COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 24 08 2020
accepted: 17 10 2020
pubmed: 23 10 2020
medline: 29 12 2020
entrez: 22 10 2020
Statut: epublish

Résumé

COVID-19-associated pulmonary aspergillosis (CAPA) was recently reported as a potential infective complication affecting critically ill patients with acute respiratory distress syndrome following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with incidence rates varying from 8 to 33% depending on the study. However, definitive diagnosis of CAPA is challenging. Standardized diagnostic algorithms and definitions are lacking, clinicians are reticent to perform aerosol-generating bronchoalveolar lavages for galactomannan testing and microscopic and cultural examination, and questions surround the diagnostic sensitivity of different serum biomarkers. Between 11 March and 14 July 2020, the UK National Mycology Reference Laboratory received 1,267 serum and respiratory samples from 719 critically ill UK patients with COVID-19 and suspected pulmonary aspergillosis. The laboratory also received 46 isolates of

Identifiants

pubmed: 33087440
pii: JCM.02136-20
doi: 10.1128/JCM.02136-20
pmc: PMC7771443
pii:
doi:

Substances chimiques

Antigens, Fungal 0
Mannans 0
Proteoglycans 0
beta-Glucans 0
galactomannan 11078-30-1
polysaccharide-K 3X48A86C8K
Galactose X2RN3Q8DNE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MR/N006364/2
Pays : United Kingdom

Informations de copyright

© Crown copyright 2020.

Références

Schwartz IS, Friedman DZP, Zapernick L, Dingle TC, Lee N, Sligl W, Zelyas N, Smith SW. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta. Can Clin Infect Dis. 2020;6:ciaa007.
doi: 10.1093/cid/ciaa007
Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou ER, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–792.
doi: 10.1016/S2213-2600(18)30274-1
Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, Lagrou K, Wilmer A, Jorens P, Hermans G. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38:1761–1768.
doi: 10.1007/s00134-012-2673-2
Ku YH, Chan KS, Yang CC, Tan CK, Chuang YC, Yu WL. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc. 2017;116:660–670.
doi: 10.1016/j.jfma.2017.06.002
Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Calandra T, Clancy CJ, Cornely OA, Chiller T, Depuydt P, Giacobbe DR, Janssen NAF, Kullberg BJ, Lagrou K, Lass-Flörl C, Lewis RE, Liu PW, Lortholary O, Maertens J, Martin-Loeches I, Nguyen MH, Patterson TF, Rogers TR, Schouten JA, Spriet I, Vanderbeke L, Wauters J, van de Veerdonk FL. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46:1524–1512.
doi: 10.1007/s00134-020-06091-6
Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, Dimopoulos G, Paiva JA, Misset B, Rello J, Vandewoude K, Vogelaers D. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64.
doi: 10.1164/rccm.201111-1978OC
Bassetti M, Giacobbe DR, Grecchi C, Rebuffi C, Zuccaro V, Scudeller L. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis. J Infect. 2020;81:131–146.
doi: 10.1016/j.jinf.2020.03.065
Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782–800.
doi: 10.1183/09031936.00062206
Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.
doi: 10.1186/cc4823
Xu Z, Li S, Tian S, Li H, Kong LQ. Full spectrum of COVID-19 severity still being depicted. Lancet. 2020;395:947–948.
doi: 10.1016/S0140-6736(20)30308-1
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–911.
doi: 10.1001/jamainternmed.2020.0994
Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, Cornely OA, S Perlin D, Lass-Flörl C, Hoenigl M. COVID-19 associated pulmonary aspergillosis (CAPA): from immunology to treatment. J Fungi. 2020;6:91.
doi: 10.3390/jof6020091
Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin AG, Thellier M, Piarroux R, Demoule A, Fekkar A. Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis. 2020;26:1636–1637.
doi: 10.3201/eid2607.201603
Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020;24:299.
doi: 10.1186/s13054-020-03046-7
Antinori S, Rech R, Galimberti L, Castelli A, Angeli E, Fossali T, Bernasconi D, Covizzi A, Bonazzetti C, Torre A, Carsana L, Tonello C, Zerbi P, Nebuloni M. Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: a diagnostic challenge. Travel Med Infect Dis. 2020;26 May:101752.
doi: 10.1016/j.tmaid.2020.101752
Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU: a case report. Med Mycol Case Rep. 2020.
doi: 10.1016/j.mmcr.2020.05.001
Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8:e48–e49.
doi: 10.1016/S2213-2600(20)30237-X
Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R, Mertes H, Dits H, Van Regenmortel N. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10:71.
doi: 10.1186/s13613-020-00686-4
Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, Hallek M, Jung N, Klein F, Persigehl T, Rybniker J, Kochanek M, Böll B, Shimabukuro-Vornhagen A. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:528–534.
doi: 10.1111/myc.13096
van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202:132–135.
doi: 10.1164/rccm.202004-1038LE
Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020.
doi: 10.1016/j.cmi.2020.07.010
Santana MF, Pivoto G, Alexandre MAA, Baía-da-Silva DC, Borba MGDS, Val FA, Brito-Sousa JD, Melo GC, Monteiro WM, Souza JVB, Pinheiro SB, Ferreira LCL, Naveca FG, Nascimento VA, Corado ALG, Hajjar LA, Silva Neto JR, Siva GAV, Pasqualotto AC, Lacerda MVG. Confirmed invasive pulmonary aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. Rev Soc Bras Med Trop. 2020;53:e20200401.
doi: 10.1590/0037-8682-0401-2020
Verweij PE, Gangneux J-P, Bassetti M, Brüggemann RJM, Cornely OA, Koehler P, Lass-Flörl C, van de Veerdonk FL, Chakrabarti A, Hoenigl M. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020;1:e53–e55.
doi: 10.1016/S2666-5247(20)30027-6
Wahidi MM, Lamb C, Murgu S, Musani A, Shojaee S, Sachdeva A, Maldonado F, Mahmood K, Kinsey M, Sethi S, Mahajan A, Majid A, Keyes C, Alraiyes AH, Sung A, Hsia D, Eapen G. American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or confirmed COVID-19 infection. J Bronchology Interv Pulmonol. 2020;10:1097.
doi: 10.1097/LBR.0000000000000681
Talento AF, Dunne K, Joyce EA, Palmer M, Johnson E, White PL, Springer J, Loeffler J, Ryan T, Collins D, Rogers TR. A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit. J Crit Care. 2017;40:119–127.
doi: 10.1016/j.jcrc.2017.03.025
Eigl S, Hoenigl M, Spiess B, Heldt S, Prattes J, Neumeister P, Wolfler A, Rabensteiner J, Prueller F, Krause R, Reinwald M, Flick H, Buchheidt D, Boch T. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Med Mycol. 2107;55:528–534.
doi: 10.1093/mmy/myw102
White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. 2006;42:479–486.
doi: 10.1086/499949
White PL, Mengoli C, Bretagne S, Cuenca-Estrella M, Finnstrom N, Klingspor L, Melchers WJ, McCulloch E, Barnes RA, Donnelly JP, Loeffler J. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol. 2011;49:3842–3848.
doi: 10.1128/JCM.05316-11
Borman AM, Palmer MD, Delhaes L, Carrère J, Favennec L, Ranque S, Gangneux JP, Horré R, Bouchara JP. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med Mycol. 2010;48 Suppl 1:S88–S97.
doi: 10.3109/13693786.2010.511287
Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 2008.
Gangneux JP, Reizine F, Guegan H, Pinceaux K, Le Balch P, Prat E, Pelletier R, Belaz S, Le Souhaitier M, Le Tulzo Y, Seguin P, Lederlin M, Tadié JM, Robert-Gangneux F. Is the COVID-19 pandemic a good time to include Aspergillus molecular detection to categorize aspergillosis in ICU patients? A monocentric experience. J Fungi. 2020;6:E105.
doi: 10.3390/jof6030105
Boch T, Reinwald M, Spiess B, Liebregts T, Schellongowski P, Meybohm P, Rath PM, Steinmann J, Trinkmann F, Britsch S, Michels JD, Jabbour C, Hofmann WK, Buchheidt D. Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1-3-beta-d-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study. J Crit Care. 2018;47:198–203.
doi: 10.1016/j.jcrc.2018.07.001
Flikweert AW, Grootenboers MJJH, Yick DCY, Du Mée AWF, van der Meer NJM, Rettig TCD, Kant MKM. Late histopathologic characteristics of critically ill COVID-19 patients: different phenotypes without evidence of invasive aspergillosis, a case series. J Crit Care. 2020;59:149–155.
doi: 10.1016/j.jcrc.2020.07.002
Fekkar A, Poignon C, Blaize M, Lampros A. Fungal infection during COVID-19: does Aspergillus mean secondary invasive aspergillosis?. Am J Respir Crit Care Med. 2020;202:902–903.
doi: 10.1164/rccm.202005-1945LE
Armstrong-James D, Youngs J, Bicanic T, Abdolrasouli A, Denning DW, Johnson E, Mehra V, Pagliuca T, Patel B, Rhodes J, Schelenz S, Shah A, van de Veerdonk FL, Verweij PE, White PL, Fisher MC. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J. 2020;56:2002554.
doi: 10.1183/13993003.02554-2020

Auteurs

Andrew M Borman (AM)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom Andy.Borman@nbt.nhs.uk.
Medical Research Council Centre for Medical Mycology (MRC CMM), University of Exeter, Exeter, United Kingdom.

Michael D Palmer (MD)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Mark Fraser (M)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Zoe Patterson (Z)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Ciara Mann (C)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Debra Oliver (D)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Christopher J Linton (CJ)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Martin Gough (M)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Phillipa Brown (P)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Agnieszka Dzietczyk (A)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Michelle Hedley (M)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Sue McLachlan (S)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Julie King (J)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.

Elizabeth M Johnson (EM)

UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom.
Medical Research Council Centre for Medical Mycology (MRC CMM), University of Exeter, Exeter, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH